MG
NBIX icon

Marex Group’s Neurocrine Biosciences NBIX Stock Holding History

Marex Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,920
Closed -$648K – 1275
2026
Q1 		$648K Buy
4,920
+768
+18% +$102K ﹤0.01% 558
2025
Q4 		$589K Buy
4,152
+2,209
+114% +$320K ﹤0.01% 516
2025
Q3 		$273K Buy
+1,943
New +$263K ﹤0.01% 649
2025
Q2 		– Sell
-2,111
Closed -$233K – 841
2025
Q1 		$233K Buy
+2,111
New +$267K ﹤0.01% 541
2024
Q4 		– Sell
-1,764
Closed -$203K – 778
2024
Q3 		$203K Buy
+1,764
New +$242K ﹤0.01% 480

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marex Group's NBIX Position: Q2 2026 in Review

Marex Group sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 4,920 shares — an estimated $648K sold.

Marex Group first reported a position in NBIX in Q3 2024 and held it in 5 quarters. The position peaked at $648K in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Marex Group reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Marex Group sold 4,920 Neurocrine Biosciences shares in Q2 2026, an estimated $648K.
  • Marex Group first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 5 quarters.
  • Marex Group's Neurocrine Biosciences position peaked at $648K in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.